文献速递性腺与生殖内分泌垂体与肾上腺疾病

促性腺激素治疗用于男性低促性腺激素性性腺功能减退症婴儿的小青春期诱导

Gonadotropin Therapy for Mini-Puberty Induction in Male Infants With Hypogonadotropic Hypogonadism.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本系统评价纳入11项研究、71例男性低促性腺激素性性腺功能减退症婴儿,评估促性腺激素诱导小青春期的效果。促性腺激素使阴茎长度和抑制素B浓度显著升高(P=0.0007),73%(n=62)患者实现部分或完全睾丸下降。结论支持促性腺激素诱导小青春期的疗效,但数据异质性和治疗方式差异限制可靠性与推广性。

要点

  • 促性腺激素治疗使男性CHH婴儿阴茎长度和抑制素B浓度显著升高(P=0.0007)。
  • 73%(n=62)患者实现部分或完全睾丸下降。
  • 数据异质性和治疗方式差异限制结论的可靠性与推广性。

核心结论

  • 促性腺激素诱导小青春期具有疗效,但数据差异和治疗方式变异限制可靠性与推广性。

研究设计与样本

  • 遵循PRISMA指南的系统评价,检索11个数据库(2023年8月),方案注册于PROSPERO(CRD42023453080)。
  • 采用Cochrane非随机干预研究偏倚风险评估工具评价证据质量。
  • 双人共识筛选767篇摘要和66篇全文后纳入11项研究,来自7个国家,共71例男性婴儿,其中12例为Kallmann综合征。
  • 治疗启动中位年龄4.2个月(范围0.25-57个月),随访3至10年。

主要发现

  • 促性腺激素给药方式为持续皮下输注(n=35)或皮下注射(n=36),因治疗差异合并分析。
  • 促性腺激素使阴茎长度和抑制素B浓度出现统计学显著升高(P=0.0007)。
  • 73%(n=62)患者实现部分或完全睾丸下降。

局限性

  • 数据差异和治疗方式变异限制可靠性与推广性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Congenital hypogonadotropic hypogonadism (CHH) is defined as an isolated deficiency of gonadotropin hormones. Mini-puberty, a transient postnatal activation of the hypothalamic-pituitary-gonadal axis in healthy infants, provides a window of opportunity to diagnose and treat CHH. Currently, in male infants with CHH, testosterone is used to increase phallus size. However, gonadotropin replacement could additionally promote testicular descent and development, particularly relating to Sertoli cells. We conducted a systematic review of the effectiveness of gonadotropin therapy in stimulating mini-puberty related outcomes in male infants with CHH. EVIDENCE ACQUISITION: In line with PRISMA guidelines, a systematic review of 11 databases was carried out (August 2023). Evidence quality was assessed using the Cochrane Risk of Bias for Non-Randomised Studies of Interventions tool. Protocol registered on PROSPERO (CRD42023453080). EVIDENCE SYNTHESIS: After a double-consensus screen of 767 abstracts and 66 full texts, 11 studies were included from 7 countries. A total of 71 male infants were enrolled, 12 with Kallmann syndrome. Median age at treatment initiation was 4.2 months (range, 0.25-57 months) and follow-up ranged from 3 to 10 years. Gonadotropin therapy was administered using continuous subcutaneous infusion (n = 35) or subcutaneous injection (n = 36). Due to treatment variability, modalities were combined for data synthesis. Gonadotropins induced a statistically significant increase in penile length and inhibin B concentration (P = .0007) and led to partial or full testicular descent in 73% (n = 62) of patients. CONCLUSION: This systematic review provides unique evidence supporting the efficacy of gonadotropins for induction of mini-puberty. However, the reliability and generalizability are limited due to disparate data and treatment modality variation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rhys-Evans S, d'Aniello F, Alexander EC, et al. Gonadotropin Therapy for Mini-Puberty Induction in Male Infants With Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab. 2025. PMID: 39673783. doi:10.1210/clinem/dgae874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。